Lisata Therapeutics, Inc. (LSTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 27, 2024, reports the results of the 2024 Annual Meeting of Stockholders for Lisata Therapeutics, Inc., a Delaware corporation. The filing details the voting outcomes for six proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity plan amendments rather than financial performance.
Material Changes and Voting Results
Stockholders approved all six proposals presented at the Annual Meeting. Key outcomes include:
- Director Elections (Proposal 1): Re-election of Class II directors Gregory B. Brown, M.D., Heidi Henson, and David J. Mazzo, Ph.D. All received majority support, though significant "against" votes were recorded (ranging from approximately 310,000 to 375,000).
- Equity Incentive Plan Amendment (Proposal 2): Approval to increase the number of shares available under the 2018 Equity Incentive Compensation Plan by 600,000 shares.
- "Evergreen" Provision (Proposal 3): Approval of a three-year automatic increase provision for the 2018 Equity Incentive Compensation Plan, effective January 1, 2025. The increase will be the lesser of 5% of outstanding shares or a number determined by the plan administrator.
- Employee Stock Purchase Plan (Proposal 4): Approval to increase shares available under the 2017 plan from 68,333 to 113,333 shares.
- Auditor Ratification (Proposal 5): Ratification of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Executive Compensation (Proposal 6): Non-binding advisory approval of named executive officer compensation.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, operational outlook, specific risks, or contingencies. The document serves strictly as a disclosure of shareholder voting results.
Investor Verification Checklist
- Verify the impact of the new "evergreen" provision on future share dilution starting in 2025.
- Review the definitive Proxy Statement (Schedule 14A filed April 29, 2024) for detailed biographies of the re-elected directors and full compensation details.
- Monitor the company's cash position and burn rate, as this filing does not disclose current liquidity levels.
- Assess the significance of the "against" votes for directors and the equity plan amendments relative to total shares outstanding.